EPCAM and cancer: The negative selection-based CTC isolation scheme features the capability to harvest viable, label-free CTCs, particularly all possible CTCs, including conventionally defined EpCAM+ CTCs and EMT-transformed cancer cells, from the blood samples of cancer patients.